Price (delayed)
$0.45
Market cap
$18.73M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.33
Enterprise value
$4.98M
Highlights
RLYB's debt has dropped by 61% year-on-year and by 33% since the previous quarter
The EPS is up by 28% year-on-year and by 16% since the previous quarter
The quick ratio has grown by 14% from the previous quarter but it has contracted by 12% YoY
The equity has declined by 42% year-on-year and by 13% since the previous quarter
Key stats
What are the main financial stats of RLYB
MarketValuationsEarnings
Shares outstanding
41.61M
Market cap
$18.73M
Enterprise value
$4.98M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.3
Price to sales (P/S)
30.81
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
7.82
Revenue
$636,000
Gross profit
$636,000
Operating income
-$60.5M
Net income
-$57.78M
EBIT
-$57.78M
EBITDA
-$57.64M
Free cash flow
-$49.28M
Per shareBalance sheetLiquidity
EPS
-$1.33
EPS diluted
-$1.33
Free cash flow per share
-$1.13
Book value per share
$1.49
Revenue per share
$0.01
TBVPS
$1.56
Total assets
$68.11M
Total liabilities
$6.45M
Debt
$154,000
Equity
$61.65M
Working capital
$61.6M
Debt to equity
0
Current ratio
10.87
Quick ratio
10.5
Net debt/EBITDA
0.24
MarginsEfficiencyDividend
EBITDA margin
-9,063.5%
Gross margin
100%
Net margin
-9,084.1%
Operating margin
-9,511.9%
Return on assets
-68.2%
Return on equity
-76.6%
Return on invested capital
-101.3%
Return on capital employed
-93.4%
Return on sales
-9,084.1%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
RLYB stock price
How has the Rallybio stock price performed over time
Intraday
-19.21%
1 week
-29.7%
1 month
-37.47%
1 year
-71.52%
YTD
-53.13%
QTD
-31.25%
Financial performance
How have Rallybio's revenue and profit performed over time
Revenue
$636,000
Gross profit
$636,000
Operating income
-$60.5M
Net income
-$57.78M
Gross margin
100%
Net margin
-9,084.1%
RLYB financials
Rallybio's net income has increased by 23% YoY and by 14% QoQ
RLYB's operating income is up by 23% year-on-year and by 14% since the previous quarter
Rallybio's operating margin has increased by 19% from the previous quarter
RLYB's net margin is up by 19% since the previous quarter
Growth
What is Rallybio's growth rate over time
RLYB growth chart
Valuation
What is Rallybio stock price valuation
P/E
N/A
P/B
0.3
P/S
30.81
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
7.82
Price to earnings (P/E)
The EPS is up by 28% year-on-year and by 16% since the previous quarter
Price to book (P/B)
RLYB's price to book (P/B) is 57% lower than its last 4 quarters average of 0.7
The equity has declined by 42% year-on-year and by 13% since the previous quarter
Price to sales (P/S)
RLYB's revenue is up by 6% from the previous quarter
Efficiency
How efficient is Rallybio business performance
The ROIC has declined by 40% year-on-year
RLYB's return on equity is down by 35% year-on-year
Rallybio's return on assets has decreased by 28% YoY
The ROS is up by 19% since the previous quarter
Dividends
What is RLYB's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for RLYB.
Financial health
How did Rallybio financials performed over time
Assets vs liabilities
The total assets has declined by 41% year-on-year and by 14% since the previous quarter
Rallybio's total liabilities has decreased by 32% YoY and by 21% from the previous quarter
Debt vs equity
RLYB's debt is 100% smaller than its equity
RLYB's debt has dropped by 61% year-on-year and by 33% since the previous quarter
The equity has declined by 42% year-on-year and by 13% since the previous quarter
Balance sheet
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified. Data from 
and Sharadar.